Left ventricular ejection fraction (EF) remains the major parameter for diagnosis,
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Reverse left ventricular (LV) remodeling and recovery of LV function are associated with
improved clinical outcomes in patients with heart failure with reduced ejection fraction. A …

Background Patients with pre-existing heart failure (HF) are likely at higher risk for adverse
outcomes in coronavirus disease-2019 (COVID-19), but data on this population are sparse …

A organização de uma diretriz clínica é tarefa complexa, que necessariamente deve
envolver planejamento prévio, coordenação apropriada, revisão aprofundada da literatura …

Aims The objectives of the present study were to describe epidemiology and outcomes in
ambulatory heart failure (HF) patients stratified by left ventricular ejection fraction (LVEF) and …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

Rationale: Umbilical cord–derived mesenchymal stem cells (UC-MSC) are easily accessible
and expanded in vitro, possess distinct properties, and improve myocardial remodeling and …

Background The new category of heart failure (HF), HF with mid‐range left ventricular
ejection fraction (LVEF)(HFmrEF), has recently been proposed. However, the clinical …

With modern treatments for heart failure with reduced ejection fraction (EF), indicative of
impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are …